Evidence map›Paper›PMID 34495462›Full record

SynthesisMetabolic brain disease2021

Oxytocin levels in individuals with schizophrenia are high in cerebrospinal fluid but low in serum: A systematic review and meta-analysis : Oxytocin and Schizophrenia.

Yazmín Hernández-Díaz, Thelma Beatriz González-Castro, Carlos Alfonso Tovilla-Zárate, María Lilia López-Narváez, Alma Delia Genis-Mendoza, Rosa Giannina Castillo-Avila, Miguel Ángel Ramos-Méndez, Isela Esther Juárez-Rojop

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Yazmín Hernández-DíazDivisión Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, Tabasco, México.
Thelma Beatriz González-CastroDivisión Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, Tabasco, México.
Carlos Alfonso Tovilla-ZárateDivisión Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Comalcalco, Tabasco, México. alfonso_tovillaz@yahoo.com.mx.
María Lilia López-NarváezHospital General de Yajalón, Secretaría de Salud, Yajalón, Chiapas, México.
Alma Delia Genis-MendozaLaboratorio de Genómica de Enfermedades Psiquiátricas y Neurodegenerativas, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Rosa Giannina Castillo-AvilaDivisión Académica de Ciencias de La Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México.ORCID http://orcid.org/0000-0001-8170-8171
Miguel Ángel Ramos-MéndezDivisión Académica de Ciencias de La Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México.
Isela Esther Juárez-RojopDivisión Académica de Ciencias de La Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México.
Universidad Juárez Autónoma de Tabasco · MXNational Institute of Genomic Medicine · MXSecretaria de Salud · HN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is a debilitating mental illness. Levels of oxytocin have been proposed as a biomarker of schizophrenia; however, the observed levels of oxytocin in individuals with schizophrenia have been inconsistent across studies. We performed a meta-analysis to evaluate oxytocin levels in plasma, serum and cerebrospinal fluid to see if there are statistically different concentrations between individuals with schizophrenia and the comparison group. The meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Following the inclusion and exclusion criteria, 14 studies were included in the meta-analysis. The quality of the study was evaluated by the Newcastle-Ottawa Scale (NOS). A random-effects model was performed using the Comprehensive Meta-analysis software with the standardized mean difference (SMD) and 95% confidence intervals (CIs). Serum oxytocin levels in individuals with schizophrenia were significantly lower than that in comparison group (SMD =  - 1.74, 95% CI =  - 3.22 to - 0.26, p = 0.02) but cerebrospinal fluid oxytocin levels in individuals with schizophrenia were significantly higher than those in the comparison group (SMD = 0.55, 95% CI = 0.05 to 1.04, p = 0.03). Our results suggest that oxytocin levels in cerebrospinal fluid are increased in individuals with schizophrenia but decreased in serum. Therefore, the oxytocin system dysregulation may play a role in the pathophysiology of schizophrenia and it should be measured in more populations for a possible implementation as a biomarker of schizophrenia.

Indexed as

OxytocinSchizophreniaBiomarkersHumansBiomarkersOxytocinCerebrospinal fluidOxytocinSchizophreniaserum

Identifiers

PMID34495462
OpenAlexW3196717270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.